Hauber AB, Lam A, Fleishmann J, Wilson MR. European economic evaluation of OROS hydromorphone in the management of severe chronic cancer and non-cancer pain. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece. [abstract] Value Health. 2008 Nov; 11(6):A640.
Fagiolini A, Mauskopf JA, Wilson MR, Harnett J, Sanders KN, Kremer C. Development of a cost-effectiveness model for evaluating treatment of acute mania/mixed mania in bipolar i disorder. Poster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders; February 2008.
Earnshaw SR, Wilson MR, Blanchette C. Cost-effectiveness of salmeterol/fluticasone propionate in the treatment of COPD: estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the Annual Meeting of the American College of Chest Physicians; October 2007.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Earnshaw SR, Okazawa M, Wilson MR, Blanchette C. Estimating the annual number of exacerbations in chronic obstructive pulmonary disease. Poster presented at the International Conference of the American Thoracic Society; May 2007.
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Wilson MR, Van Houtven CH, Stearns S, Clipp EC. Depression and missed work among informal caregivers of older individuals with dementia. J Fam Econ Issues. 2007;28(4):684-98.